News from map pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jan 02, 2013, 05:15 ET MAP Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the 31st Annual J.P. Morgan Healthcare Conference on...

Nov 21, 2012, 05:00 ET MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA Resubmission for LEVADEX®

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that its New Drug Application (NDA) resubmission for LEVADEX® orally inhaled migraine drug...

Nov 08, 2012, 04:30 ET MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the following investor conferences: Lazard Capital Markets...

Nov 01, 2012, 04:10 ET MAP Pharmaceuticals Reports Third Quarter of 2012 Financial Results

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the third quarter ended September 30, 2012. The net loss for the three ...

Oct 16, 2012, 07:00 ET MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has resubmitted its New Drug Application (NDA) to the United States Food and Drug...

Aug 29, 2012, 05:00 ET MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the underwriter of its recent public offering of common stock fully exercised its...

Aug 09, 2012, 07:00 ET MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the following investor conferences: Canaccord Genuity 32nd...

Aug 01, 2012, 09:05 ET MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the pricing of an underwritten public offering of 3,880,598 shares of its common stock at a...

Jul 31, 2012, 04:02 ET MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that it intends to offer and sell shares of its common stock in an underwritten public...

Jul 24, 2012, 07:00 ET MAP Pharmaceuticals Reports Second Quarter of 2012 Financial Results

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2012. The net loss for the three...

Jun 25, 2012, 07:00 ET MAP Pharmaceuticals Provides Update Following Meeting with FDA for LEVADEX® (dihydroergotamine) New Drug Application

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company completed an End-of-Review meeting with the United States Food and Drug...

Jun 21, 2012, 04:05 ET MAP Pharmaceuticals to Present Data on LEVADEX® at the 54th Annual Scientific Meeting of the American Headache Society

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present data on LEVADEX® (formerly MAP0004), an orally inhaled...

May 04, 2012, 07:00 ET MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the first quarter ended March 31, 2012. The net loss for the first...

May 01, 2012, 07:00 ET MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in May 2012:...

Apr 12, 2012, 04:05 ET MAP Pharmaceuticals Provides Update on LEVADEX® Program

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on LEVADEX®, the Company's investigational orally inhaled drug for the potential...

Mar 29, 2012, 07:00 ET MAP Pharmaceuticals Reports 2011 Fourth Quarter and Year End Financial Results

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2011. The net loss for...

Mar 26, 2012, 07:23 ET MAP Pharmaceuticals Receives Complete Response Letter from FDA for LEVADEX® (dihydroergotamine) NDA

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response...

Feb 23, 2012, 07:00 ET MAP Pharmaceuticals Issued Additional U.S. Patent for Methods of Achieving Rapid Treatment of Migraine Based Upon Pharmacokinetic Profile

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Patent and Trademark Office (USPTO) issued to the Company U.S. Patent ...

Feb 08, 2012, 07:00 ET MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in February 2012:...

Jan 17, 2012, 07:00 ET MAP Pharmaceuticals Appoints W. James O'Shea to Board of Directors

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of W. James O'Shea to its Board of Directors. Mr. O'Shea brings to the Board ...

Jan 04, 2012, 07:00 ET MAP Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the 30th Annual J.P. Morgan Healthcare Conference on...

Nov 08, 2011, 07:00 ET MAP Pharmaceuticals Reports Third Quarter of 2011 Financial Results

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the third quarter ended September 30, 2011. Net income for the three...

Sep 06, 2011, 06:35 ET MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in September: Stifel ...

Aug 11, 2011, 07:05 ET MAP Pharmaceuticals Issued U.S. Patent for Methods of Achieving Rapid Relief of Migraine and Minimizing Side Effects Based Upon Pharmacokinetic Profile

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Patent and Trademark Office (USPTO) issued to the Company U.S. Patent ...

Aug 11, 2011, 07:00 ET MAP Pharmaceuticals to Present at Upcoming Investor Conference

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the 2011 Wedbush Life Sciences: Management Access...